{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    8,
    10,
    11,
    15,
    32,
    33,
    39,
    40,
    41,
    45,
    46,
    49,
    50
  ],
  "modelUsed": "claude-opus-4-5",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Section 4.1.1 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.1.1",
        "sectionTitle": "Cohort A",
        "description": "Reference to total enrollment based on safety and PK data in Schema"
      },
      {
        "id": "ref_2",
        "name": "Section 4.1.2 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.1.2",
        "sectionTitle": "Cohort B",
        "description": "Reference for additional details on Cohort B in Schema"
      },
      {
        "id": "ref_3",
        "name": "Dosing Regimen Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.3.2",
        "sectionTitle": "Rationale for Cohort B Dose Selection",
        "description": "Reference to dosing regimen details in Schema and Section 6.1"
      },
      {
        "id": "ref_4",
        "name": "Section 6.1 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.1",
        "sectionTitle": "Study Intervention(s) Administered",
        "description": "Reference to dosing regimen in Schema"
      },
      {
        "id": "ref_5",
        "name": "Sample Size Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.2",
        "sectionTitle": "Sample Size Determination",
        "description": "Reference for sample size in Sub-Cohorts B2 and B3 in Schema"
      },
      {
        "id": "ref_6",
        "name": "Section 10.3 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Adverse Events: Definitions and Procedures",
        "description": "Reference added to AE collection row in Schedule of Activities"
      },
      {
        "id": "ref_7",
        "name": "Section 9.2.2 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.2.2",
        "sectionTitle": "Cohort B Sample Size",
        "description": "Reference for recommendation to open enrollment to Cohort B"
      },
      {
        "id": "ref_8",
        "name": "Section 2.1 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2.1",
        "sectionTitle": "Study Rationale",
        "description": "Reference to bioavailability calculation using available PK data"
      },
      {
        "id": "ref_9",
        "name": "Appendix 4 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.4",
        "sectionTitle": "Contraceptive Guidance",
        "description": "Reference to contraceptive methods with failure rate <1% per year"
      },
      {
        "id": "ref_10",
        "name": "Appendix 1 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.1",
        "sectionTitle": "Regulatory, Ethical, and Study Oversight Considerations",
        "description": "Reference for informed consent requirements"
      },
      {
        "id": "ref_11",
        "name": "Appendix 2 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference for pregnancy testing and hypersensitivity tests"
      },
      {
        "id": "ref_12",
        "name": "Appendix 6 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.6",
        "sectionTitle": "Restricted and Prohibited Concomitant Therapy",
        "description": "Reference for aspirin use and NSAID restrictions"
      },
      {
        "id": "ref_13",
        "name": "Section 6.5.1.8 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.5.1.8",
        "sectionTitle": "Supportive Care by Adverse Event of Special Interest",
        "description": "Reference for hypertension and proteinuria treatment criteria"
      },
      {
        "id": "ref_14",
        "name": "Section 6.6.1 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6.1",
        "sectionTitle": "AESI Dose-Modification Guidelines",
        "description": "Reference for adverse event of special interest dose-modification"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Gastrointestinal-GEJ and NSCLC participants are allowed to be on therapeutic-dose anticoagulation if they are on a stable dose (minimum duration 14 days) of oral anticoagulant or low molecular weight heparin. If receiving warfarin, the participant must have an INR ≤3.0 and no active bleeding.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Inclusion Criteria",
        "pageNumber": 40
      },
      {
        "id": "annot_2",
        "text": "Refer to Section 4.1.1 for total enrollment, based on safety and PK data.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schema",
        "pageNumber": 16
      },
      {
        "id": "annot_3",
        "text": "Refer to Section 4.1.2 for additional details.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schema",
        "pageNumber": 16
      },
      {
        "id": "annot_4",
        "text": "Maximal proposed weekly doses are indicated. This dose will be administered once per week, with the LD given on Cycle 1 Day 1, except in Cohort B1 that will start with 875 mg SC QW MD without LD.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schema",
        "pageNumber": 16
      },
      {
        "id": "annot_5",
        "text": "Refer to Sections 4.3.2 and 6.1 for the dosing regimen.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schema",
        "pageNumber": 16
      },
      {
        "id": "annot_6",
        "text": "Sample size in Sub-Cohorts B2 and B3 (if opened) determined by PK and safety data, per Sections 4.1.2 and 9.2.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schema",
        "pageNumber": 16
      },
      {
        "id": "annot_7",
        "text": "Central venous access device placement must occur at least 7 days prior to enrollment.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Exclusion Criteria",
        "pageNumber": 42
      },
      {
        "id": "annot_8",
        "text": "For each weekly dose in Cycle 1, the following criteria must be fulfilled to administer ramucirumab SC: Total bilirubin ≤1.5x ULN or baseline, ALT and AST ≤3x ULN if baseline <1.5x ULN, ALT and AST ≤2x baseline if baseline ≥1.5x ULN",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Treatment Requirements",
        "pageNumber": 47
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "e",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-02-26",
        "description": "Protocol Amendment e - substantial amendment to enable investigation of additional dosage regimens based on preliminary interim analysis data from Study I4T-MC-JVDT",
        "amendmentNumber": "Amendment e"
      },
      {
        "id": "ver_2",
        "versionNumber": "d",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-01-14",
        "description": "Protocol Amendment d",
        "amendmentNumber": "Amendment d"
      },
      {
        "id": "ver_3",
        "versionNumber": "c",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-11-05",
        "description": "Protocol Amendment c",
        "amendmentNumber": "Amendment c"
      },
      {
        "id": "ver_4",
        "versionNumber": "b",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-10-02",
        "description": "Protocol Amendment b",
        "amendmentNumber": "Amendment b"
      },
      {
        "id": "ver_5",
        "versionNumber": "a",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-09-14",
        "description": "Protocol Amendment a",
        "amendmentNumber": "Amendment a"
      },
      {
        "id": "ver_6",
        "versionNumber": "Original",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-05-21",
        "description": "Original Protocol"
      }
    ],
    "summary": {
      "referenceCount": 14,
      "annotationCount": 8,
      "versionCount": 6
    }
  }
}